Mmc stock price recently tested the $210 resistance

MMC stock price recently tested the $210 resistance zone, but short-term technical indicators like RSI suggest a consolidation phase before another potential breakout. Analysts expect sector rotation to benefit insurance and consulting plays. While the first narrative suggests the stock is undervalued based on analyst expectations, a simple look at the commonly used valuation ratio against the broader U.S. insurance industry signals that shares may actually be on the expensive side. So, which measure should investors trust more when thinking about long-term value? In the last 24 hours, Marsh & McLennan Companies (MMC) has experienced several price target adjustments by analysts, reflecting mixed market sentiments. UBS analyst Brian Meredith lowered the firm’s price target due to unspecified reasons but maintained a Buy rating. Keefe Bruyette also reduced their price target, citing gradually decelerating property and casualty rate increases and macroeconomic uncertainty as factors likely to pressure sentiment on insurance brokers. Wells Fargo similarly lowered their price target, noting that while the company’s earnings showed an organic beat, there was a slowdown in consulting organic growth and cautiousness regarding the economic outlook. Despite these adjustments, Marsh & McLennan reported strong Q2 2025 growth with a 12% increase in revenue, driven by business momentum and strategic acquisitions, alongside a 10% dividend increase, highlighting its robust financial position. MMC stock price attracted renewed attention after the Federal Reserve hinted at possible interest rate cuts later this year, potentially improving capital flows into high-quality, dividend-paying equities.